Orchestra BioMed Holdings, Inc. (OBIO)
(Real Time Quote from BATS)
$7.63 USD
-0.43 (-5.34%)
Updated Jul 26, 2024 10:34 AM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Orchestra BioMed Holdings, Inc. (OBIO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$16.33 | $20.00 | $14.00 | 102.61% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Orchestra BioMed Holdings, Inc. comes to $16.33. The forecasts range from a low of $14.00 to a high of $20.00. The average price target represents an increase of 102.61% from the last closing price of $8.06.
Analyst Price Targets (3 )
Broker Rating
Orchestra BioMed Holdings, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on three recommendations.
Of the four recommendations deriving the current ABR, four are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/25/2024 | B. Riley Securities | Kyle Bauser | Strong Buy | Strong Buy |
7/23/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/28/2024 | Piper Sandler | Matthew O'Brien | Strong Buy | Strong Buy |
3/28/2024 | Chardan Capital Markets | Keay T Nakae | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 4 |
Average Target Price | $16.33 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 252 |
Current Quarter EPS Est: | -0.41 |